8-K: Zevra Sells SDX Portfolio, Resolves Litigation for $50M

Zevra Therapeutics has sold its SDX portfolio, including AZSTARYS and KP1077, to Commave Therapeutics for $50 million, simultaneously resolving a pending lawsuit and repaying its $63 million term loan.

Summary

• Zevra Therapeutics entered into an Asset Purchase and Settlement Agreement with Commave Therapeutics SA on March 13, 2026.
• Zevra sold its entire serdexmethylphenidate (SDX) portfolio, including AZSTARYS (KP415) and KP1077, to Commave.
• Commave will pay Zevra a total of $50.0 million in cash, with $25.0 million paid upon execution, $20.0 million within ten business days, and $5.0 million upon delivery of certain records.
• The agreement resolves litigation (Commave Therapeutics SA v. Zevra Therapeutics, Inc., C.A. No. 2024-0920-LWW) related to the AZSTARYS License Agreement from September 3, 2019.
• The AZSTARYS License Agreement has been terminated, and both parties have released each other from claims arising from the litigation or the agreement.
• Zevra granted Commave a worldwide, royalty-free, fully paid-up, perpetual, irrevocable license for SDX and SDX products under Zevra's retained patents and know-how.
• On March 12, 2026, Zevra fully repaid its $63.0 million senior secured term loan, which included approximately $3.0 million in accrued paid-in-kind interest.
• The repayment terminated the Credit Agreement dated April 5, 2024, and released all associated liens and security interests.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development, as Zevra has significantly improved its financial position by becoming debt-free and gaining substantial cash, while resolving a legal dispute and sharpening its strategic focus on rare diseases.

Positives

• Received $50.0 million in cash from the sale of the SDX portfolio.
• Resolved ongoing litigation with Commave Therapeutics SA, eliminating legal costs and uncertainty.
• Achieved a debt-free balance sheet by repaying the $63.0 million senior secured term loan, enhancing financial flexibility.
• Terminated the AZSTARYS License Agreement, simplifying Zevra's operational structure.
• Management expressed confidence in the programs being in capable hands and excitement for Zevra's next chapter focused on rare diseases.

Negatives

• Divested the entire serdexmethylphenidate (SDX) portfolio, including AZSTARYS and KP1077, which were previously part of the company's assets.
• Granted Commave a worldwide, royalty-free, fully paid-up, perpetual, non-terminable, and irrevocable license for SDX and SDX products under Zevra's retained patents and know-how, meaning no future royalties from these assets.

Risks

• The press release contains forward-looking statements subject to known and unknown uncertainties, risks, and other important factors that may cause actual results to differ materially.
• These factors are described in detail in the Risk Factors section of Zevra's Annual Report on Form 10-K for the year ended December 31, 2025, and other SEC filings.

Future Outlook

Zevra's management is excited to focus on the company's next chapter, emphasizing its mission to redefine possibilities for patients with rare diseases. The company aims to broaden access through geographic expansion, progress its pipeline toward key milestones, and deliver meaningful therapeutics, leveraging its commercial-stage lead product for Niemann-Pick disease type C as a foundation.

Management Comments

• "We are pleased to have reached a mutually beneficial agreement with Commave regarding the sale of our entire SDX portfolio."
• "Over the years, we have enjoyed a productive partnership with Commave, and we are confident these programs are in capable hands."
• "We are excited to turn the page to Zevra's next chapter and remain focused on our mission of redefining what's possible for patients living with rare diseases."

Industry Context

StockSavvy.ai notes that this divestiture allows Zevra to streamline its focus on its core rare disease pipeline, a common strategic move in the specialized pharmaceutical sector. By shedding assets and resolving litigation, Zevra enhances its financial flexibility, potentially enabling more targeted investments in its Niemann-Pick disease type C program and other rare disease candidates, aligning with a trend of biopharma companies optimizing portfolios for higher-value, niche markets.

Legal Proceedings

• Resolution of litigation captioned Commave Therapeutics SA v. Zevra Therapeutics, Inc., C.A. No. 2024-0920-LWW, pending in the Court of Chancery of the State of Delaware.
• The litigation arose from claims under the Collaboration and License Agreement dated September 3, 2019 (AZSTARYS License Agreement).
• As part of the Asset Purchase and Settlement Agreement, both parties released each other from all claims related to the litigation or the AZSTARYS License Agreement.
• A stipulation of dismissal with prejudice of the Litigation is to be filed within three business days following March 13, 2026.

Stakeholder Impact

• Shareholders: Expected to benefit from a stronger, debt-free balance sheet, enhanced financial flexibility, and a clearer strategic focus on rare diseases. The resolution of litigation removes a source of uncertainty and potential legal costs.
• Creditors: The Credit Agreement with HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP has been fully repaid and terminated, releasing all liens.
• Employees: The company's renewed focus on rare diseases and pipeline progression may offer stability and new opportunities within that specialized area.
• Customers/Patients: Zevra's stated mission to redefine what's possible for patients living with rare diseases, including broadening access and progressing its pipeline, suggests a continued commitment to its patient base.

Next Steps

• Commave Therapeutics SA is obligated to pay Zevra $20.0 million within ten business days following March 13, 2026.
• Commave Therapeutics SA is obligated to pay Zevra $5.0 million within three days following the delivery of certain manufacturing records and patent books and records.
• Zevra and Commave are required to file a stipulation of dismissal with prejudice of the Litigation with the Court of Chancery of the State of Delaware within three business days following March 13, 2026.
• Zevra plans to focus on broadening access through geographic expansion opportunities for its lead product.
• Zevra intends to progress its pipeline toward key milestones.
• Zevra aims to deliver meaningful therapeutics for rare diseases.

Key Dates

Recommendation

The company has significantly de-risked its financial position by becoming debt-free and securing a substantial cash inflow of $50 million, while simultaneously resolving a costly and distracting legal dispute. This strategic move allows Zevra to focus entirely on its core rare disease pipeline, which is a high-growth, high-margin sector. The enhanced financial flexibility and clear strategic direction make ZVRA an attractive investment for long-term growth.

Keywords

Zevra Therapeutics, ZVRA, Commave Therapeutics, SDX portfolio, AZSTARYS, KP1077, Asset Sale, Litigation Settlement, Debt Repayment, Rare Disease, Pharmaceuticals, Biotechnology, SEC Filing, 8-K